No IV Formulation of Lamotrigine is Available
Lamotrigine (Lamictal) does not have an FDA-approved intravenous formulation available for clinical use 1, 2. The drug is only available in oral formulations (tablets, chewable dispersible tablets, and orally disintegrating tablets).
Clinical Evidence
The most authoritative evidence comes from the 2014 American College of Emergency Physicians/American Academy of Neurology clinical practice guidelines, which explicitly state in their comprehensive table of antiepileptic medications: "IV not available" for lamotrigine 1.
Oral Loading Strategy (When IV is Not an Option)
When resuming lamotrigine therapy in the emergency department or acute care setting, the guidelines recommend:
- Dose: 6.5 mg/kg single oral load
- Strict criteria apply:
- Patient must have been on lamotrigine for >6 months previously
- No history of rash or intolerance
- Off lamotrigine for <5 days only
- Adverse effects: Mild, transient nausea
- Critical warning: Do NOT load if history of rash or patient not previously on lamotrigine 1
Research on Experimental IV Formulation
One small research study (n=20) evaluated an experimental stable-labeled IV formulation complexed with 2-hydroxypropyl-β-cyclodextrin at a 50 mg dose 3. This was used solely for pharmacokinetic research purposes and demonstrated safety in that limited context. However, this formulation is not commercially available and has no FDA approval for clinical use.
Alternative Strategies When Oral Route is Not Feasible
If a patient cannot take oral medications and requires antiepileptic coverage:
Consider alternative agents with IV formulations:
- Levetiracetam: 1,500 mg oral load or rapid IV loading up to 60 mg/kg 1
- Valproate: Up to 30 mg/kg IV at maximum rate of 10 mg/kg/min 1
- Fosphenytoin: 18 PE/kg IV at maximum rate of 150 PE/min 1
- Lacosamide: Oral and IV formulations available 1
Critical Safety Consideration
The absence of an IV formulation is particularly relevant given lamotrigine's serious rash risk, including Stevens-Johnson syndrome and toxic epidermal necrolysis 2. The carefully titrated oral dosing schedule exists specifically to minimize this life-threatening complication, making rapid IV administration potentially dangerous even if a formulation existed.